Substance-P antagonists: A new treatment for depression?

Lancet

Volumn 352, Issue 9141, 1998, Pages 1644-1646

  Nutt, D ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; BRAIN MONOAMINE; NEUROTRANSMITTER; PAROXETINE; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUBSTANCE P RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; IRRITABILITY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR DENSITY; SEXUAL DYSFUNCTION; SHORT SURVEY; SPINAL CORD;

EID: 0032556440     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61444-4     Document Type: Note

References (8)

1. RM Snider JW Constantine III Lowe JA A potent nonpeptide antagonist of the substance P (NK) receptor Science 251 1991 435 437
2. MS Kramer N Cutler J Feighner Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
3. PL Delgado LH Price HL Miller Serotonin and the neurobiology of depression: effects of tryptophan depletion in drug-free depressed patients Arch Gen Psychiatry 51 1994 865 874
4. CJ Bell DJ Nutt Serotonin and panic Br J Psychiatry 172 1998 465 471
5. S Rasmussen E Hackett E DuNoff A 2-year study of sertraline in the treatment of obsessive compulsive disorder Int Clin Psychopharmacol 12 1997 309 316
6. JRT Davidson Pharmacotherapy of social anxiety disorder J Clin Psychiatry 59 1998 47 53
7. TGM Hokfeldt M-N Castel P Morino X Zhan A Dangerlind General overview of neuropepties Blook FE Kupfer DJ Psychopharmacology: the fourth generation of progress 1995 Raven Press New York 483 492
8. CJL Murray AD Lopez Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study Lancet 349 1997 1498 1504